drugset / Trial / NCT04468087

Antiviral Agents Against COVID-19 Infection

NCT04468087

Phase 2/3 Completed 256 enrolled Hospital do Coracao
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A key strategy in the treatment of COVID-19 would be to find an effective antiviral agent that would decrease the peak viral load and, consequently, the associated degree of immunopathological damage that follows this phase. The clinically approved substances considered for this study are used for treatment of other virus diseases, like HIV (atazanavir) and HCV (sofosbuvir and daclatasvir). Severe progression of COVID-19 among patients under treatment for these aforementioned viruses is empirical less common. Besides, the clinical rationale, there are pre-clinical evidence pointing out that patients with COVID-19 could benefit from treatments with atazanavir, sofosbuvir and daclatasvir.

Timeline

Start
2021-02-15
Primary completion
2021-08-04
Completion
2021-08-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified 300 mg
Subject Daclatasvir Small molecule 60 mg
Subject Sofosbuvir Small molecule 400 mg

Indications